6-Nitro-2,3,4,9-tetrahydro-1H-pyridol<3,4-b>indol-1-on | 17952-86-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-Nitro-2,3,4,9-tetrahydro-1H-pyridol<3,4-b>indol-1-on
• 英文别名: 6-nitro-2,3,4,9-tetrahydro-β-carbolin-1-one；6-Nitro-2,3,4,9-tetrahydro-β-carbolin-1-on；6-Nitro-2,3,4,9-tetrahydro-beta-carbolin-1-one；6-nitro-2,3,4,9-tetrahydropyrido[3,4-b]indol-1-one
• CAS: 17952-86-2
• 化学式: C₁₁H₉N₃O₃
• mdl: MFCD00227015
• 分子量: 231.211
• InChiKey: OGWVNBMJFPRUIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  90.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-Nitro-2,3,4,9-tetrahydro-1H-pyridol<3,4-b>indol-1-on 在 sodium hydroxide 、 palladium on activated charcoal 、 溶剂黄146 作用下， 生成 5-氨基-3-(2-氨基-乙基)-4,7-二羟基-吲哚-2-羧酸
  参考文献：
  名称：

  881.色胺，咔啉和相关化合物。第三部分 1-甲基-和1：N-二甲基-色胺

  摘要：

  DOI：

  10.1039/jr9560004593
• 作为产物：
  描述：

  piperidine-2,3-dione-3-(4-nitro-phenylhydrazone) 在 PPA 作用下， 生成 6-Nitro-2,3,4,9-tetrahydro-1H-pyridol<3,4-b>indol-1-on
  参考文献：
  名称：

  881.色胺，咔啉和相关化合物。第三部分 1-甲基-和1：N-二甲基-色胺

  摘要：

  DOI：

  10.1039/jr9560004593

文献信息

• Method for reducing intraocular pressure using indole derivatives
  申请人：——

  公开号：US20020037887A1

  公开（公告）日：2002-03-28

  The present invention provides a method of reducing intraocular pressure by administering pharmaceutical compositions comprising indole derivatives. The pharmaceutical compositions useful in this invention comprise indole derivatives and melatonin analogs of Formulae I-IV. A preferred embodiment is a method of lowering intraocular pressure using 5-(methoxycarbonylamino)-N-acetyltryptamine (5-MCA-NAT), also known as GR 135531, which has a prolonged duration of action and greater efficacy in lowering intraocular pressure compared to melatonin. The present invention further provides a method of treating disorders associated with ocular hypertension, and a method of treating various forms of glaucoma; the method comprises administering an effective dose of a pharmacuetical composition comprising an indole derivative with or without agents commonly used to treat such disorders. 1

  本发明提供了一种通过给予包含吲哚衍生物的药物组合物来降低眼压的方法。本发明中有用的药物组合物包括吲哚衍生物和公式I-IV的褪黑激素类似物。一种首选实施方式是使用5-(甲氧羰基氨基)-N-乙酰色氨酸（5-MCA-NAT），也称为GR 135531，来降低眼压，其作用持续时间较长，并且在降低眼压方面比褪黑激素具有更高的功效。本发明还提供了一种治疗与眼压升高相关的疾病的方法，以及一种治疗各种青光眼形式的方法；该方法包括给予包含吲哚衍生物的药物组合物的有效剂量，可选择性地与通常用于治疗此类疾病的药物一起使用。
• [EN] CARBOLINE AND BETACARBOLINE DERIVATIVES FOR USE AS HDAC ENZYME INHIBITORS<br/>[FR] DERIVES DE CARBOLINE ET DE BETACARBOLINE INHIBITEURS DE L'ENZYME HDAC
  申请人：CHROMA THERAPEUTICS LTD

  公开号：WO2004113336A1

  公开（公告）日：2004-12-29

  Compounds of formula (IA) and (IB) are inhibitors of histone deacetylase activity and useful for the treatment of, inter alia, cancers: wherein fused rings A1 and A2 are optionally substituted; linker radical R1 represents a radical of formula

  式（IA）和（IB）的化合物是组蛋白去乙酰化酶活性的抑制剂，用于治疗癌症等疾病：其中融合的环A1和A2可以选择性地被取代；连接基团R1代表一个公式的基团。
• Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
  申请人：Anderson R. David

  公开号：US20050137220A1

  公开（公告）日：2005-06-23

  A method is described for inhibiting mitogen activated protein kinase-activated protein kinase-2 in a subject in need of such inhibition, where the method involves administering to the subject a beta-carboline MK-2 inhibiting compound, or a pharmaceutically acceptable salt thereof.

  本文描述了一种用于抑制需要这种抑制的受试者中的有丝分裂原活化蛋白激酶激活蛋白激酶-2的方法，其中该方法涉及向受试者施用一种β-喀啉MK-2抑制化合物或其药学上可接受的盐。
• From pyrroles to 1-oxo-2,3,4,9-tetrahydro-1H-β-carbolines: A new class of orally bioavailable mGluR1 antagonists
  作者：Romano Di Fabio、Fabrizio Micheli、Giuseppe Alvaro、Paolo Cavanni、Daniele Donati、Tatiana Gagliardi、Gabriele Fontana、Riccardo Giovannini、Micaela Maffeis、Anna Mingardi、Maria Elvira Tranquillini、Giovanni Vitulli

  DOI：10.1016/j.bmcl.2007.01.055

  日期：2007.4

  Exploiting the SAR of the known pyrrole derivatives, a new class of mGluR1 antagonists was designed by replacement of the pyrrole core with an indole scaffold and consequent cyclization of the C-2 position into a tricyclic beta-carboline template. The appropriate exploration of the position C-6 with a combination of H-bond acceptor groups coupled with bulky/lipophilic moieties led to the discovery of a new series of mGluR1 antagonists. These compounds exhibited a non-competitive behavior, excellent pharmacokinetic properties, and good in vivo activity in animal models of acute and chronic pain, after oral administration. (c) 2007 Elsevier Ltd. All rights reserved.
• REHSE K.; FISCHER T.; MAYBAUER R., ARCH. PHARM., 1980, 313, NO 4, 379-381
  作者：REHSE K.、 FISCHER T.、 MAYBAUER R.

  DOI：——

  日期：——